Novavax Promotes John J. Trizzino to Expanded Role as Chief Business Officer and Chief Financial Officer
March 14 2018 - 4:08PM
GAITHERSBURG, Md., March 14, 2018 (GLOBE NEWSWIRE)
-- Novavax, Inc., (Nasdaq:NVAX) today announced the promotion of
John J. Trizzino to Senior Vice President, Chief Business Officer
(CBO) and Chief Financial Officer (CFO). Mr. Trizzino has been
serving as Senior Vice President, Commercial Operations, since
2014. As CBO at Novavax, he is now responsible for all
pre-commercial and commercial launch strategy and execution as well
as public relations. As CFO, he is now responsible for financial
reporting, corporate funding, and investor relations.
"At this critical inflection point
for Novavax, during which we are readying to become a commercial
company, John is the right person to step into this expanded role,"
said Stanley C. Erck, Novavax President and CEO. "John's history as
a strong executive leader coupled with his background in
commercial/business development and corporate/financial operations
will play an integral role as we continue to progress the clinical
development of our pipeline of vaccines towards the
marketplace."
Mr. Trizzino originally joined Novavax in 2009
with a broad range of experiences in small to large publicly-held
companies. He has an extensive background in the vaccine market
with previous roles overseeing commercialization, vaccine policy,
strategic development, business development, financing, investor
relations and public relations. During his tenure as CEO of
Immunovaccine Inc., Mr. Trizzino successfully led the company into
clinical development of its lead candidate, while successfully
securing the required funding commitments in the equity market as
well as non-dilutive sources. Prior to his tenures at Novavax and
Immunovaccine, Mr. Trizzino had leadership responsibilities at
MedImmune, LLC, an AstraZeneca company, ID Biomedical and Henry
Schein, Inc., all focused on infectious disease vaccine
markets.
"With Novavax poised to bring the
world's first RSV vaccine to market as we, in parallel, advance our
seasonal NanoFlu(TM) influenza vaccines, I am thrilled to take on
this expanded role that includes driving investor interest and
leading our financial strategy," said Mr. Trizzino. "I am proud to
be part of the Novavax team that has taken us to this point and
look forward to advancing our development activities for the
combined benefit of global public health and the company's
financial success."
About
Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage biotechnology company committed to delivering novel
products to prevent infectious diseases. Our RSV and influenza
nanoparticle vaccine candidates are Novavax' most advanced clinical
programs and are at the forefront of the Company's efforts to
improve global health. Additional information about Novavax is
available on the Company's website, novavax.com.
Forward-Looking Statements
Statements herein relating to the
future of Novavax and the ongoing development of its vaccine and
adjuvant products are forward-looking statements. Novavax cautions
that these forward looking statements are subject to numerous risks
and uncertainties, which could cause actual results to differ
materially from those expressed or implied by such statements.
These risks and uncertainties include those identified under the
heading "Risk Factors" in the Novavax Annual Report on Form 10-K
for the year ended December 31, 2017 as filed with the Securities
and Exchange Commission (SEC). We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these and other
risks and uncertainties. The forward-looking statements in this
press release speak only as of the date of this document, and we
undertake no obligation to update or revise any of the statements.
Our business is subject to substantial risks and uncertainties,
including those referenced above. Investors, potential investors,
and others should give careful consideration to these risks and
uncertainties.
Contact:
Investors
Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506
Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024